Adagene Inc. (FRA:978)
Germany · Delayed Price · Currency is EUR | Market Cap | 221.87M +131.0% |
| Revenue (ttm) | 8.13M +8,902.4% |
| Net Income | -17.95M |
| EPS | -0.35 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Open | 3.160 |
| Previous Close | 3.280 |
| Day's Range | 3.160 - 3.340 |
| 52-Week Range | 1.180 - 4.040 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Adagene
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 ... [Read more]
Financial Performance
In 2025, Adagene's revenue was $7.67 million, an increase of 7332.76% compared to the previous year's $103,204. Losses were -$17.61 million, -47.32% less than in 2024.
Financial numbers in USD Financial StatementsNews
Adagene to Participate in Three Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel ...
Adagene Earnings release: Q2 2026
Adagene released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has...
Adagene Slides: Corporate presentation
Adagene has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Adagene Transcript: Stifel 2026 Targeted Oncology Virtual Forum
The session highlighted advances in masked antibody technology, with ADG126 showing strong efficacy and safety in late-line MSS-CRC. Strategic collaborations with Incyte and Sanofi expand development into new combinations and tumor types, supported by a recent $70M financing.
Adagene Slides: Investor presentation
Adagene has posted slides in relation to its latest quarterly earnings report, which was published on May 19, 2026.
Adagene to Participate in Two Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based thera...
Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR
Adagene (ADAG) presented new data from two ongoing Phase 1b/2 studies of muzastotug in triple combination regimens at the American Association of Cancer Research annual meeting 2026, held April 17-22…
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively...
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
SAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and developm...
Adagene price target raised to $10 from $9 at Guggenheim
Guggenheim raised the firm’s price target on Adagene (ADAG) to $10 from $9 and keeps a Buy rating on the shares. The firm is updating its model for FY25 earnings,…
Adagene Slides: Investor presentation
Adagene has posted slides in relation to its latest quarterly earnings report, which was published on April 3, 2026.
Adagene 18.666M share Spot Secondary priced at $3.75
Leerink and LifeSci Capital acted as joint book running managers for the offering.
Adagene enters pact with Incyte for combination of muzastotug, INCA33890
Adagene (ADAG) announced a clinical collaboration with Incyte (INCY) to evaluate the combination of muzastotug and INCA33890, a TGFbetaR2 PD-1 bispecific antibody, in patients with microsatellite stab...
Adagene announces results from the latest data cut of muzastotug study
Adagene (ADAG) announced results from the latest data cut from its Phase 1b/2 study of muzastotug in patients with advanced microsatellite stable colorectal cancer with no liver metastases. FDA has…
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a company committed to transforming the discovery and development of novel ant...
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
Dose-Dependent Efficacy Results : As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement o...
Adagene reports FY25 EPS (24c) vs (51c) last year
Reports FY25 revenue $7.7M vs $103,000 last year. “Our clinical data for muzastotug plus pembrolizumab consistently demonstrate potent, dose-dependent efficacy,” said Peter Luo, Ph.D., Chairman and Pr...
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, ...
Adagene Earnings release: Q4 2025
Adagene released its Q4 2025 earnings on April 1, 2026, summarizing the period's financial results.
Adagene Annual report: Q4 2025
Adagene has published its Q4 2025 annual report on April 1, 2026.
Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based the...
Adagene Transcript: Leerink Global Healthcare Conference 2026
ADG126 demonstrates strong efficacy and safety in late-line MSS CRC, with higher doses yielding better response rates and durability. Strategic collaborations and pipeline expansion target additional indications and novel combinations, with upcoming data expected to further validate the program.
Adagene Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
ADG126, a masked anti-CTLA-4 antibody, is showing promising efficacy and safety in late-line MSS-CRC without liver metastases, with response rates up to 29% and median survival of 19–20 months. Strategic collaborations, notably with Sanofi, support ongoing trials and future expansion.